Hot Biotechs (fka HOTBIO)

[Ruellit]

More on UNVC
From the 10Q for period ending March 31, 2003:

Revenues for the three month period ending March 31, 2003 increased by $ 1,600,627 (245%) as compared to the comparable period ended March 31, 2002, primarily as a result of PPSI's initial use of their group purchasing arrangement for the distribution of pharmaceuticals, which contributed revenues of $1,681,242. During the quarter ended March 31, 2002, PPSI has commenced the distribution of prescription drugs though its group purchasing arrangement, which will be a continuing source of revenues for Univec, while Univec continues to manufacture, sell and license the syringe and medical waste products.